Tessa Romero
Stock Analyst at JP Morgan
(4.37)
# 350
Out of 5,090 analysts
72
Total ratings
51.79%
Success rate
21.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $37 → $20 | $27.73 | -27.88% | 7 | Nov 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $9.55 | +57.07% | 8 | Nov 20, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $57 → $60 | $45.01 | +33.30% | 3 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $45.02 | +4.40% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $3.32 | +7,821.69% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $27.44 | +12.97% | 11 | Nov 17, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $20.28 | -16.17% | 7 | Nov 14, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $23.59 | +44.13% | 11 | Nov 14, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $2.22 | - | 5 | Sep 16, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $65.67 | -19.29% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $9.35 | +6.95% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $27.75 | +36.94% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $16.66 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $17.74 | +63.47% | 3 | Aug 13, 2024 |
Agios Pharmaceuticals
Nov 21, 2025
Maintains: Neutral
Price Target: $37 → $20
Current: $27.73
Upside: -27.88%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $9.55
Upside: +57.07%
Xenon Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $57 → $60
Current: $45.01
Upside: +33.30%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $45.02
Upside: +4.40%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.32
Upside: +7,821.69%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $27.44
Upside: +12.97%
Dyne Therapeutics
Nov 14, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $20.28
Upside: -16.17%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $23.59
Upside: +44.13%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.22
Upside: -
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $65.67
Upside: -19.29%
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $9.35
Upside: +6.95%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $27.75
Upside: +36.94%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $16.66
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $17.74
Upside: +63.47%